Cargando…

Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases

BACKGROUND: It is not clear which known adverse prognostic factors of neuroblastoma are closely associated with tumor recurrence after complete response. We analyzed the factors for post-remission recurrence in children with neuroblastoma through a retrospective study. METHODS: A total of 179 childr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fan, Zhang, Weiling, Hu, Huimin, Zhang, Yi, Li, Jing, Huang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747547/
https://www.ncbi.nlm.nih.gov/pubmed/35023974
http://dx.doi.org/10.2147/CMAR.S343648
_version_ 1784630859826987008
author Li, Fan
Zhang, Weiling
Hu, Huimin
Zhang, Yi
Li, Jing
Huang, Dongsheng
author_facet Li, Fan
Zhang, Weiling
Hu, Huimin
Zhang, Yi
Li, Jing
Huang, Dongsheng
author_sort Li, Fan
collection PubMed
description BACKGROUND: It is not clear which known adverse prognostic factors of neuroblastoma are closely associated with tumor recurrence after complete response. We analyzed the factors for post-remission recurrence in children with neuroblastoma through a retrospective study. METHODS: A total of 179 children with neuroblastoma who achieved initial complete response were included in this study. Kaplan–Meier method and multivariate Cox regression model were used to assess the factors that may have impact on tumor recurrence after complete response. RESULTS: The 5-year overall survival rates of the entire cohort (n = 179), recurrence group (n = 86) and non-recurrence group (n = 93) were 81.9%, 66.2%, and 98.7%, respectively. The 5-year recurrence-free survival (RFS) rates of the entire cohort and the high-risk cohort were 47.3% and 31.2%, respectively. RFSs were significantly reduced in children with age ≥18 months, INSS stage 4, unfavorable histology, bone marrow metastasis, osseous metastasis, serum NSE level ≥100 ng/mL, and serum LDH level ≥1400 U/L (P < 0.05). The independent risk factors for post-remission recurrence in the entire cohort were age ≥18 months, unfavorable histology, and serum LDH level ≥1400 U/L (P < 0.05). In the high-risk cohort, the independent risk factor for recurrence was serum LDH ≥1400 U/L (P < 0.05). Based on a new recurrence risk stratification, the 5-year RFSs of the children were 93.5%, 66.4%, and 22.5% in the low-risk, intermediate-risk, and high-risk groups, respectively. The area under the ROC curve of the new stratification was 0.773 (95% CI: 0.704−0.842). CONCLUSION: Age ≥18 months, unfavorable histology, and serum LDH level ≥1400 U/L are independent risk factors for post-remission recurrence in children with neuroblastoma. A newly established recurrence risk stratification has diagnostic advantages in predicting risk of recurrence, which is especially suitable for low- and middle-income countries or regions.
format Online
Article
Text
id pubmed-8747547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87475472022-01-11 Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases Li, Fan Zhang, Weiling Hu, Huimin Zhang, Yi Li, Jing Huang, Dongsheng Cancer Manag Res Original Research BACKGROUND: It is not clear which known adverse prognostic factors of neuroblastoma are closely associated with tumor recurrence after complete response. We analyzed the factors for post-remission recurrence in children with neuroblastoma through a retrospective study. METHODS: A total of 179 children with neuroblastoma who achieved initial complete response were included in this study. Kaplan–Meier method and multivariate Cox regression model were used to assess the factors that may have impact on tumor recurrence after complete response. RESULTS: The 5-year overall survival rates of the entire cohort (n = 179), recurrence group (n = 86) and non-recurrence group (n = 93) were 81.9%, 66.2%, and 98.7%, respectively. The 5-year recurrence-free survival (RFS) rates of the entire cohort and the high-risk cohort were 47.3% and 31.2%, respectively. RFSs were significantly reduced in children with age ≥18 months, INSS stage 4, unfavorable histology, bone marrow metastasis, osseous metastasis, serum NSE level ≥100 ng/mL, and serum LDH level ≥1400 U/L (P < 0.05). The independent risk factors for post-remission recurrence in the entire cohort were age ≥18 months, unfavorable histology, and serum LDH level ≥1400 U/L (P < 0.05). In the high-risk cohort, the independent risk factor for recurrence was serum LDH ≥1400 U/L (P < 0.05). Based on a new recurrence risk stratification, the 5-year RFSs of the children were 93.5%, 66.4%, and 22.5% in the low-risk, intermediate-risk, and high-risk groups, respectively. The area under the ROC curve of the new stratification was 0.773 (95% CI: 0.704−0.842). CONCLUSION: Age ≥18 months, unfavorable histology, and serum LDH level ≥1400 U/L are independent risk factors for post-remission recurrence in children with neuroblastoma. A newly established recurrence risk stratification has diagnostic advantages in predicting risk of recurrence, which is especially suitable for low- and middle-income countries or regions. Dove 2022-01-06 /pmc/articles/PMC8747547/ /pubmed/35023974 http://dx.doi.org/10.2147/CMAR.S343648 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Fan
Zhang, Weiling
Hu, Huimin
Zhang, Yi
Li, Jing
Huang, Dongsheng
Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title_full Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title_fullStr Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title_full_unstemmed Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title_short Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases
title_sort factors of recurrence after complete response in children with neuroblastoma: a 16-year retrospective study of 179 cases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747547/
https://www.ncbi.nlm.nih.gov/pubmed/35023974
http://dx.doi.org/10.2147/CMAR.S343648
work_keys_str_mv AT lifan factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases
AT zhangweiling factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases
AT huhuimin factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases
AT zhangyi factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases
AT lijing factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases
AT huangdongsheng factorsofrecurrenceaftercompleteresponseinchildrenwithneuroblastomaa16yearretrospectivestudyof179cases